Lanxess Takes Over Flexsys Businesses

Lanxess has agreed to acquire two businesses from Flexsys, a division of U.S.-based Solutia Inc. (St. Louis, Mo.) to strengthen the portfolio of its Rubber Chemicals business unit.

Lanxess will acquire the primary accelerator business as well as the anti-reversion agent Perkalink 900. Employees will not be transferred to Lanxess. Both parties have decided not to disclose the acquisition prices. The acquisition of the primary accelerator business requires approval from the relevant antitrust authorities.

Lanxess will take over selected parts of Flexsys' primary accelerators business and integrate them into its existing production facilities in Kallo, Belgium, and Bushy Park, S.C.  Lanxess is already a leading supplier of primary accelerators, with its Vulkacit brand, and has invested €10 million over the last two years to upgrade its Kallo world-scale plant.

Accelerators help determine the speed of the vulcanization process and help to achieve the desired properties of the finished rubber product. Vulcanization is a chemical process for converting rubber into more durable materials via the addition of sulfur.

In addition, Lanxess will take over from Flexsys the anti-reversion agent Perkalink 900. It is one of the leading products to avoid the risk of reversion during the vulcanization process and thus improve the service life of tires, as well as other technical rubber products. It also complements Lanxess' existing specialties portfolio, which includes products such as the anti-reversion agent Vulcuren.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.